<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Pediatrics. Consilium Medicum</journal-id><journal-title-group><journal-title xml:lang="en">Pediatrics. Consilium Medicum</journal-title><trans-title-group xml:lang="ru"><trans-title>Педиатрия. Consilium Medicum</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2658-6630</issn><issn publication-format="electronic">2658-6622</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">100631</article-id><article-id pub-id-type="doi">10.26442/26586630.2021.4.201341</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Gut microbiota and obesity. Can probiotics help?</article-title><trans-title-group xml:lang="ru"><trans-title>Микробиота кишечника и ожирение. Могут ли помочь пробиотики?</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4200-4598</contrib-id><name-alternatives><name xml:lang="en"><surname>Zakharova</surname><given-names>Irina N.</given-names></name><name xml:lang="ru"><surname>Захарова</surname><given-names>Ирина Николаевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.), Prof.</p></bio><bio xml:lang="ru"><p>д-р мед. наук, проф., зав. каф. педиатрии, засл. врач России</p></bio><email>zakharova-rmapo@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5684-7575</contrib-id><name-alternatives><name xml:lang="en"><surname>Berezhnaya</surname><given-names>Irina V.</given-names></name><name xml:lang="ru"><surname>Бережная</surname><given-names>Ирина Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>канд. мед. наук, доц. каф. педиатрии</p></bio><email>berezhnaya-irina26@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7994-3751</contrib-id><name-alternatives><name xml:lang="en"><surname>Simakova</surname><given-names>Mariia A.</given-names></name><name xml:lang="ru"><surname>Симакова</surname><given-names>Мария Александровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Graduate Student</p></bio><bio xml:lang="ru"><p>аспирант каф. педиатрии</p></bio><email>simakova131@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Russian Medical Academy of Continuous Professional Education</institution></aff><aff><institution xml:lang="ru">ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2021-12-15" publication-format="electronic"><day>15</day><month>12</month><year>2021</year></pub-date><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>330</fpage><lpage>334</lpage><history><date date-type="received" iso-8601-date="2022-02-13"><day>13</day><month>02</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-02-13"><day>13</day><month>02</month><year>2022</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2021, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2021, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://pediatria.orscience.ru/2658-6630/article/view/100631">https://pediatria.orscience.ru/2658-6630/article/view/100631</self-uri><abstract xml:lang="en"><p>The high prevalence of obesity in children and adolescents, the complexity of therapy, a large number of comorbid conditions dictate the need for ongoing research into the causes of obesity and methods for its prevention. One of the newest and most promising aspects to study influencing the formation of obesity is the gut microbiota. The proposed mechanisms linking the gut microbiota to obesity are realized through strain-specific effects of bacteria on changes in the host's metabolism. Probiotics affect the microbiota directly by modulating its composition and indirectly through bacteriocins produced by probiotic bacteria. There is great scientific interest in the use of probiotics as part of therapy or for the prevention of obesity.</p></abstract><trans-abstract xml:lang="ru"><p>Высокая распространенность ожирения среди детей и подростков, сложность терапии, большое количество коморбидных состояний диктуют необходимость постоянного изучения причин развития ожирения и методов его профилактики. К одним из наиболее новых и перспективных аспектов для изучения, влияющих на формирование ожирения, относят микробиоту кишечника. Предлагаемые механизмы, связывающие микробиоту кишечника с ожирением, реализуются через штамм-специфичное влияние бактерий на изменения метаболизма организма-хозяина. Пробиотики воздействуют на микробиоту напрямую, модулируя ее состав, и косвенно – через бактериоцины, продуцируемые пробиотическими бактериями. Большой научный интерес вызывает применение пробиотиков в составе терапии или для профилактики ожирения.</p></trans-abstract><kwd-group xml:lang="en"><kwd>obesity</kwd><kwd>children</kwd><kwd>multistrain</kwd><kwd>multispecies symbiotic</kwd><kwd>short-chain fatty acids</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>ожирение</kwd><kwd>дети</kwd><kwd>мультиштаммовый</kwd><kwd>мультивидовой симбиотик</kwd><kwd>короткоцепочечные жирные кислоты</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Bäckhed F, Roswall J, Peng Y, et al. Dynamics and Stabilization of the Human Gut Microbiome during the First Year of Life. Cell Host Microbe. 2015;17(5):690-703.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Muscogiuri G, Cantone E, Cassarano S, et al.; on behalf of the Obesity Programs of nutrition, Education, Research and Assessment (OPERA) group. Gut microbiota: a new path to treat obesity. Int J Obes Suppl. 2019;9(1):10-9.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Moossavi S, Azad MB. Quantifying and Interpreting the Association between Early-Life Gut Microbiota Composition and Childhood Obesity. mBio. 2019;10(1):e02787-18.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Stanislawski MA, Dabelea D, Wagner BD, et al. Gut Microbiota in the First 2 Years of Life and the Association with Body Mass Index at Age 12 in a Norwegian Birth Cohort. mBio. 2018;9(5):e01751-18.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Haddad EN, Sugino KY, Kerver JM, et al. The infant gut microbiota at 12 months of age is associated with human milk exposure but not with maternal pre-pregnancy body mass index or infant BMI-for-age z-scores. Curr Res Physiol. 2021;4:94-102.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Tun HM, Bridgman SL, Chari R, et al.; Canadian Healthy Infant Longitudinal Development (CHILD) Study Investigators. Roles of Birth Mode and Infant Gut Microbiota in Intergenerational Transmission of Overweight and Obesity From Mother to Offspring. JAMA Pediatr. 2018;172(4):368-77.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Bäckhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Sci USA. 2004;101(44):15718-23. DOI:10.1073pnas.0407076101</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Dahiya DK, Renuka, Puniya M, et al. Gut Microbiota Modulation and Its Relationship with Obesity Using Prebiotic Fibers and Probiotics: A Review. Front Microbiol. 2017;8:563. DOI:10.3389/fmicb.2017.00563</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Kasubuchi M, Hasegawa S, Hiramatsu T, et al. Dietary gut microbial metabolites, short-chain fatty acids, and host metabolic regulation. Nutrients. 2015;7(4):2839-49. DOI:10.3390/nu7042839</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes Metab Res. 2007;56:1761-72. DOI:10.2337/db06-1491</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Louis S, Tappu RM, Damms-Machado A, et al. Characterization of the gut microbial Community of Obese Patients Following a weight-loss intervention using whole Metagenome shotgun sequencing. PLoS One. 2016;11(2):e0149564. DOI:10.1371/journal.pone.0149564</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>De Silva A, Bloom SR. Gut hormones and appetite control: a focus on PYY and GLP-1 as therapeutic targets in obesity. Gut Liver. 2012;6:10-20. DOI:10.5009/gnl.2012.6.1.10</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Aron-Wisnewsky J, Gaborit B, Dutour A, Clement K. Gut microbiota and non-alcoholic fatty liver disease: new insights. Clin Microbiol Infect. 2013;19(4):338-48. DOI:10.1111/1469 0691.12140</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Million M, Maraninchi M, Henry M, et al. Obesity-associated gut microbiota is enriched in Lactobacillus reuteri and depleted in Bifidobacterium animalis and Methanobrevibacter smithii. Int J Obes. 2012;36(6):817-25.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature. 2011;473(7346):174-80. DOI:10.1038/nature09944</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Schwiertz A, Taras D, Schäfer K, et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring). 2010;18(1):190-5. DOI:10.1038/oby.2009.167</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Choi SB, Lew LC, Yeo SK, et al. Probiotics and the BSH-related cholesterol lowering mechanism: a Jekyll and Hyde scenario. Crit Rev Biotechnol. 2015;35(3):392-401. DOI:10.3109/07388551.2014.889077</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Jones ML, Martoni CJ, Parent M, Prakash S. Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults. Br J Nutr. 2012;107:1505-13.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Shimizu M, Hashiguchi M, Shiga T, et al. Meta-Analysis: Effects of Probiotic Supplementation on Lipid Profiles in Normal to Mildly Hypercholesterolemic Individuals. PLOS One. 2015;16:116. DOI:10.1371/journal.pone.0139795</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Shavakhi A, Minakari M, Firouzian H, et al. Effect of a Probiotic and Metformin on Liver Aminotransferases in Non-alcoholic Steatohepatitis: A Double Blind Randomized Clinical Trial. Int J Prevent Med. 2013;4(5):531-7.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Eslamparast T, Poustchi H, Zamani F, et al. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr. 2014;99:535-42.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Ардатская М.Д. Клиническое применение пищевых волокон: метод. пособие. М.: 4ТЕ Арт, 2010 [Ardatskaia MD. Klinicheskoe primenenie pishchevykh volokon: metod. posobie. Moscow: 4TE Art, 2010 (in Russian)].</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Pal S, Ho S, Gahler RJ, Wood S. Effect on body weight and composition in overweight/obese Australian adults over 12 months consumption of two different types of fibre supplementation in a randomized trial. Nutr Metab. 2016;13:82-92. DOI:10.1186/s12986-016-0141–7</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>De Bock M, Derraik JGB, Brennan CM, et al. Psyllium supplementation in adolescents improves fat distribution &amp; lipid profile: a randomized, participant-blinded, placebo-controlled, crossover trial. PLoS One. 2012;7(7):41735. DOI:10.1371/journal.pone.0041735</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Abutair AS, Naser IA, Hamed AT. Soluble fibers from psyllium improve glycemic response and body weight among diabetes type 2 patients (randomized control trial). Nutr J. 2016;15:86-93. DOI:10.1186/s12937-016-0207-4</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Копчак Д.В. Клиническое обоснование эффективности использования пре- и пробиотиков у пациентов с метаболическим синдромом и нарушенным микробиоцинозом тонкой и толстой кишки. Автореф. дис. … канд. мед. наук. СПб., 2019 [Kopchak DV. Klinicheskoe obosnovanie effektivnosti ispol'zovaniia pre- i probiotikov u patsientov s metabolicheskim sindromom i narushennym mikrobiotsinozom tonkoi i tolstoi kishki. Avtoref. dis. … kand. med. nauk. Saint Petersburg, 2019 (in Russian)].</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Juul F, Hemmingsson E. Trends in consumption of ultra-processed foods and obesity in Sweden between 1960 and 2010. Public Health Nutr. 2015;18(17):3096-7.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Neri D, Steele EM, Khandpur N, et al. Ultraprocessed food consumption and dietary nutrient profiles associated with obesity: A multicountry study of children and adolescents. Obes Rev. 2021;e13387.</mixed-citation></ref></ref-list></back></article>
